Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, has secured $60 million in funding, a clinical update for its pivotal Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, and new appointments to its Board of Directors.

The funding includes a $40 million financing round led by existing investors AMR Action Fund and BNP Paribas Asset Management Alts, consisting of approximately $18M in 1Q and $22M in 2Q. In addition, the company has received an additional $20 million under its existing contract with BARDA to continue the RESTORATIVE303 study. The proceeds of this financing will support the Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection, with topline efficacy data expected in 1H 2027.

Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is currently being evaluated in the global Phase 3 RESTORATiVE303 registrational study for the prevention of recurrent C. difficile infection.